190 related articles for article (PubMed ID: 10551966)
21. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis.
Laudes IJ; Chu JC; Sikranth S; Huber-Lang M; Guo RF; Riedemann N; Sarma JV; Schmaier AH; Ward PA
Am J Pathol; 2002 May; 160(5):1867-75. PubMed ID: 12000738
[TBL] [Abstract][Full Text] [Related]
22. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.
Dargaud Y; Desmurs-Clavel H; Marin S; Bordet JC; Poplavsky JL; Negrier C
J Thromb Haemost; 2008 Jun; 6(6):962-8. PubMed ID: 18373620
[TBL] [Abstract][Full Text] [Related]
24. Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.
Sørensen B; Spahn DR; Innerhofer P; Spannagl M; Rossaint R
Crit Care; 2011; 15(1):201. PubMed ID: 21345266
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
[TBL] [Abstract][Full Text] [Related]
26. Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model.
Grottke O; Rossaint R; Henskens Y; van Oerle R; Ten Cate H; Spronk HM
PLoS One; 2013; 8(5):e64100. PubMed ID: 23696866
[TBL] [Abstract][Full Text] [Related]
27. Activation of the coagulation cascade in patients with leptospirosis.
Chierakul W; Tientadakul P; Suputtamongkol Y; Wuthiekanun V; Phimda K; Limpaiboon R; Opartkiattikul N; White NJ; Peacock SJ; Day NP
Clin Infect Dis; 2008 Jan; 46(2):254-60. PubMed ID: 18171258
[TBL] [Abstract][Full Text] [Related]
28. Blood clotting disorders during experimental sarcocystiosis in calves.
Daugschies A; Rupp U; Rommel M
Int J Parasitol; 1998 Aug; 28(8):1187-94. PubMed ID: 9762563
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
Petăjă J; Peltola K; Sairanen H; Leijala M; Kekomäki R; Vahtera E; Siimes MA
J Thorac Cardiovasc Surg; 1996 Sep; 112(3):665-71. PubMed ID: 8800154
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
31. Different Heparin Contents in Prothrombin Complex Concentrates May Impair Blood Clotting in Outpatients With Ventricular Assist Devices Receiving Phenprocoumon.
Felli A; Zeidler P; Jilma B; Opfermann P; Holaubek C; Zimpfer D; Wadowski PP; Steinlechner B
J Cardiothorac Vasc Anesth; 2016 Jan; 30(1):96-101. PubMed ID: 26613641
[TBL] [Abstract][Full Text] [Related]
32. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
Buchanan GR; Kevy SV
Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
[TBL] [Abstract][Full Text] [Related]
33. Changes in the blood coagulation, fibrinolysis, and cytokine profile during laparoscopic and open cholecystectomy.
Schietroma M; Carlei F; Mownah A; Franchi L; Mazzotta C; Sozio A; Amicucci G
Surg Endosc; 2004 Jul; 18(7):1090-6. PubMed ID: 15136925
[TBL] [Abstract][Full Text] [Related]
34. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients.
Preston FE; Laidlaw ST; Sampson B; Kitchen S
Br J Haematol; 2002 Mar; 116(3):619-24. PubMed ID: 11849221
[TBL] [Abstract][Full Text] [Related]
35. Thromboelastometry as a supplementary tool for evaluation of hemostasis in severe sepsis and septic shock.
Andersen MG; Hvas CL; Tønnesen E; Hvas AM
Acta Anaesthesiol Scand; 2014 May; 58(5):525-33. PubMed ID: 24580049
[TBL] [Abstract][Full Text] [Related]
36. Compositional differences in commercially available prothrombin complex concentrates.
Sadeghi N; Kahn D; Sayed D; Hoppenstadt D; Jeske W; Harenberg J; Dechristopher P; Fareed J
Clin Appl Thromb Hemost; 2014 Apr; 20(3):256-69. PubMed ID: 24288386
[TBL] [Abstract][Full Text] [Related]
37. Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.
Hampton KK; Makris M; Kitchen S; Preston FE
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):637-41. PubMed ID: 1782333
[TBL] [Abstract][Full Text] [Related]
38. Biochemical comparison of seven commercially available prothrombin complex concentrates.
Kalina U; Bickhard H; Schulte S
Int J Clin Pract; 2008 Oct; 62(10):1614-22. PubMed ID: 18691229
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease.
Woodward M; Lowe GD; Rumley A; Tunstall-Pedoe H; Philippou H; Lane DA; Morrison CE
Br J Haematol; 1997 Jun; 97(4):785-97. PubMed ID: 9217177
[TBL] [Abstract][Full Text] [Related]
40. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
